Price$1.15-0.04 (-3.78%)
02:30 PM07:45 PM
News · 26 weeks42+133%
2026-04-192026-10-11
Mix2290d
- Other10(45%)
- SEC Filings5(23%)
- Insider5(23%)
- Earnings2(9%)
Latest news
25 items- SECSEC Form RW filed by RenovoRx Inc.RW - RenovoRx, Inc. (0001574094) (Filer)
- PRRenovoRx Advances TAMP™ into Borderline Resectable Pancreatic Cancer with First Patient Enrolled in Investigator-Initiated PRISM-TAMP TrialMOUNTAIN VIEW, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, announced today that the first patient has enrolled in PRISM-TAMP, "PDAC Regression and Intraoperative Surgical Margin With Neoadjuvant TAMP," an investigator-initiated trial (IIT) sponsored by the University of Vermont (UVM). One week after the IIT began, a second patient is also progressing toward TAMP treatment. PRISM-TAMP is evaluating the approved chemotherapy gemcitabine delivered through RenovoRx’s Trans-Arterial Mic
- INSIDERSEC Form 4 filed by Director Macfarlane K. Angela4 - RenovoRx, Inc. (0001574094) (Issuer)
- INSIDERSEC Form 4 filed by Director Ryan Una S4 - RenovoRx, Inc. (0001574094) (Issuer)
- INSIDERSEC Form 4 filed by Director Spiegel Robert J.4 - RenovoRx, Inc. (0001574094) (Issuer)
- INSIDERSEC Form 4 filed by Director Marton Laurence4 - RenovoRx, Inc. (0001574094) (Issuer)
- PRRenovoRx Announces Peer-Reviewed Publication Highlighting the TAMP™ Platform's Potential to Improve Chemotherapeutic Delivery for Locally Advanced Pancreatic CancerMOUNTAIN VIEW, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced the publication of a peer-reviewed case series in Case Reports in Oncology from researchers at Hackensack Meridian Health’s Jersey Shore University Medical Center. The publication describes two patients with locally advanced pancreatic cancer (LAPC), whose tumors were not surgically removable due to significant complex blood vessel involvement despite receiving extensive prior treatment. Both patients underw
- INSIDERChief Financial Officer Voll Mark was granted 80,000 shares, increasing direct ownership by 56% to 222,380 units (SEC Form 4)4 - RenovoRx, Inc. (0001574094) (Issuer)
- PRRenovoRx to Present at H.C. Wainwright 28th Annual Global Investment Conference, September 14th-16thMOUNTAIN VIEW, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced that Shaun Bagai, Chief Executive Officer, and Mark Voll, Chief Financial Officer, will present at the H.C. Wainwright 28th Annual Global Investment Conference. The conference will be held at the Lotte New York Palace Hotel in New York City, September 14-16, 2026. Mr. Bagai and Mr. Voll will discuss RenovoRx’s record second quarter revenue, driven by increasing commercial demand for RenovoCath as a standalo
- PRRenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP™ Platform’s Targeted Drug-Delivery in Locally Advanced Pancreatic CancerPK/PD Data is from a Sub-Study in the Phase III TIGeR-PaC Clinical Trial The Study Shows Approximately 51% Tumor-Site Drug Extraction, Decreased Systemic Exposure, and Significant Correlation Between Drug Metabolite Levels and Tumor Marker Reduction MOUNTAIN VIEW, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced the publication of pharmacokinetic and pharmacodynamic (PK/PD) data from a sub-study of its ongoing Phase III TIGeR-PaC clinical trial (NCT03257033) in the jou
- PRRenovoRx Regains Compliance with Nasdaq Minimum Bid Price RequirementMOUNTAIN VIEW, Calif., Aug. 21, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced that it has received written notification from The Nasdaq Stock Market LLC ("Nasdaq") confirming that the Company has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market. On August 20, 2026, the Nasdaq Listing Qualifications Staff notified RenovoRx in writing that the closing bid price of its common stock was at $1.00 per share or greater for the 10 c
- SECRenovoRx Inc. filed SEC Form 8-K: Other Events8-K - RenovoRx, Inc. (0001574094) (Filer)
- PRRenovoRx Receives Notice of Allowance for New U.S. Patent Covering RenovoCath®, an Advanced Dual-Occlusion Catheter, for Targeted Therapeutic Drug-Delivery for Cancer TreatmentMOUNTAIN VIEW, Calif., Aug. 20, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the Company’s patent application (U.S. Application No. 18/184,620) titled "Methods and Apparatuses for Delivery of Therapeutic Materials for the Treatment of Cancer." Once issued, this patent will strengthen RenovoRx’s growing U.S. intellectual property portfolio, reinforcing the Company’s differentiated approach to target
- SECSEC Form 10-Q filed by RenovoRx Inc.10-Q - RenovoRx, Inc. (0001574094) (Filer)
- SECAmendment: RenovoRx Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K/A - RenovoRx, Inc. (0001574094) (Filer)
- SECRenovoRx Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - RenovoRx, Inc. (0001574094) (Filer)
- PRRenovoRx Reports Record Second Quarter 2026 Results, Driven by Accelerating Commercial Adoption and 61% Sequential Quarterly Revenue GrowthIncreases 2026 Annual Revenue Guidance to a Range of $3.75M to $4.25M First Treatment Delivered with RenovoCath® in Patient with Sarcoma in Clinical Setting, Marking Expansion of Device to Other Solid Tumors Phase III TIGeR-PaC Trial Reaches Full Enrollment; Completion of Trial Expected in First Half 2027 with Topline Data Readout Expected in Second Half 2027 Management to Host Conference Call Today at 4:30 p.m. ET MOUNTAIN VIEW, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today
- PRRenovoRx Achieves Major Milestone with Full Enrollment in Phase III TIGeR-PaC Trial for Locally Advanced Pancreatic CancerMOUNTAIN VIEW, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, is pleased to announce completion of enrollment in the Company’s Phase III TIGeR-PaC trial in locally advanced pancreatic cancer (LAPC). As of August 7, 2026, TIGeR-PaC trial investigators have been notified by RenovoRx that patient enrollment is closing. Completion of the trial is expected during the first half of 2027, after 86 events (i.e., patient deaths) have been observed. As of August 11, 2026, 78 events have occurre
- PRRenovoRx Announces First Commercial Clinical Use of RenovoCath® in Sarcoma Patient Treatment, Marking Expansion of Targeted Drug-Delivery Device to Other Solid TumorsMOUNTAIN VIEW, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced the first commercial clinical use of RenovoCath for drug-delivery in the treatment of a patient with sarcoma at the CARTI Cancer Center Little Rock ("CARTI"). Sarcoma is a cancer that starts in the soft tissues or bones of the body. For this patient’s sarcoma case, CARTI is using RenovoRx’s RenovoCath device to deliver chemotherapy locally near the tumor rather than through traditional systemic intravenous a
- SECRenovoRx Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - RenovoRx, Inc. (0001574094) (Filer)
- PRRenovoRx to Highlight TAMP™ Platform at JonesTrading Virtual Key Opinion Leader Webinar on the Evolving Pancreatic Cancer Landscape, August 13thMOUNTAIN VIEW, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced it will participate in a JonesTrading webinar with oncology key opinion leaders (KOLs) and Shaun Bagai, Chief Executive Officer of RenovoRx, on August 13, 2026 at 1:30 p.m. ET. The webinar, The Evolving Pancreatic Cancer Landscape: The Role of RenovoRx's TAMP Platform and Emerging Clinical Advances, will be moderated by Justin Walsh, Equity Research Analyst covering the healthcare sector at JonesTrading. He
- PRRenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ETMOUNTAIN VIEW, Calif., July 29, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced that it will host its second quarter 2026 financial results and business highlights conference call on August 12, 2026, at 4:30 p.m. ET. During the call, RenovoRx management will discuss the Company’s growing revenues from commercial sales of RenovoCath as a standalone drug-delivery device, as well as increased RenovoCath adoption at high-volume U.S. cancer centers and a broader base of repeat orders from ex
- SECRenovoRx Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - RenovoRx, Inc. (0001574094) (Filer)
- SECSEC Form S-8 filed by RenovoRx Inc.S-8 - RenovoRx, Inc. (0001574094) (Filer)
- SECRenovoRx Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - RenovoRx, Inc. (0001574094) (Filer)
RNXT FAQ
6 questionsWhere does RNXT stock trade?
RenovoRx Inc. (RNXT) is listed on NASDAQ.What sector and industry is RNXT in?
RenovoRx Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did RenovoRx Inc. go public?
RenovoRx Inc. (RNXT) completed its IPO in 2021.What are analysts saying about RNXT?
RenovoRx Inc. has had 2 recent analyst actions on file. The most recent action was from Roth Capital: Buy with a $1600.00 price target on 2021-11-01. Recent price targets range from $1500.00 to $1600.00.What companies are similar to RNXT?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare RNXT side-by-side with any of them on Quantisnow.How can I track RNXT on Quantisnow?
Quantisnow aggregates RenovoRx Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow RNXT to receive live email and push alerts on every new disclosure.